



# NGS Panels for Hereditary Cancers

Genetic Testing for an Improved Prognosis

# NGS Panels for Hereditary Cancers

Genetic testing for hereditary cancers can provide life-changing results in affected patients and their relatives, accompanied by potential actionable steps. With many different applications of germline genetic testing to detect and care for cancer, we can guide you in selecting the right options to enhance the treatment of your patients suffering from hereditary cancers. Having identified genetic variants associated with oncological diseases in more than 100 different genes, we can provide a comprehensive range to foster cancer diagnosis, prognosis, treatment selection, and monitoring.

CENTOGENE's NGS panels for hereditary cancers include all relevant clinical genes, as well as genes necessary for differential diagnosis of syndromes with overlapping phenotype – therefore allowing the diagnosis of a disease that otherwise would be missed. This approach maximizes the clinical utility, de-risks panel choice, increases cost-effectiveness, and ultimately simplifies the diagnostic process.

## The CENTOGENE Advantage



Coverage of **all relevant disease-causing genes** and non-coding and coding pathogenic variants



Powered by CENTOGENE's Biodatabank, **the world's largest real-world data repository** for rare and neurodegenerative diseases



The most **up-to-date panel gene content** with the latest medical and in-house findings



**High-quality analysis for precise clinical interpretation** using advanced bioinformatics and artificial intelligence-powered tools

## Key Features and Performance

### Coverage

- $\geq 99\%$  targeted regions covered at  $\geq 20\times$
- The target region for each gene comprises all exons;  $\pm 10$  bp flanking regions; known pathogenic and likely pathogenic variants described in HGMD<sup>®</sup> and the CENTOGENE's Biodatabank, including relevant deep intronic and regulatory variants, which were known at the time of the assay design.

---

### Genes

For a complete overview of included genes, please visit:

[centogene.com/diagnostics/benefits-of-genetic-testing/medical-reporting](https://centogene.com/diagnostics/benefits-of-genetic-testing/medical-reporting)

---

### Specificity

$\geq 99.9\%$  guaranteed for all reported variants. Variants with low quality and/or unclear zygosity are confirmed by orthogonal methods (Sanger, MLPA, qPCR)

---

### CNV Sensitivity

NGS-based copy number variations (CNV) are detected with a sensitivity of above 90% for all homozygous deletions and heterozygous deletions / duplications spanning at least three consecutive exons. Heterozygous CNVs spanning less than three exons cannot reliably be detected, are therefore excluded from routine analysis, and will only be inspected and reported upon medical or technical indication.

---

### Reporting

To find more information about our medical reporting, please refer to our designated NGS Panel webpage: [centogene.com/diagnostics/ngs-panels/oncology](https://centogene.com/diagnostics/ngs-panels/oncology)

---

### TAT

15 business days

Panel	Genes Included
BRCA1, BRCA2*	<i>BRCA1, BRCA2</i>
CentoBreast	<i>ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2</i>
CentoCancer®	<i>APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, DIS3L2, EPCAM, FANCC, FH, FLCN, GALNT12, HOXB13, KIT, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, RNF43, RPS20, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3</i>
CentoCancer® Comprehensive	<i>ABRAXAS1, ACVRL1, AKT1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DDB2, DDX41, DICER1, DIS3L2, EGFR, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, EXT1, EXT2, FANCC, FH, FLCN, GALNT12, GATA2, GPC3, GREM1, HNF1A, HNF1B, HOXB13, HRAS, KIF1B, KIT, MAX, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS1, PMS2, POLD1, POLE, POLH, POT1, PRKAR1A, PRSS1, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL, REST, RET, RNF43, RPS20, RUNX1, SAMD9L, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA2, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERT, TGFBR2, TMEM127, TP53, TRIP13, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC, XRCC2, XRCC3</i>
CentoCancer® Pediatric	<i>AIP, ALK, ANKRD26, APC, ASXL1, ATM, BAP1, BLM, BMPR1A, BRAF, BUB1B, CBL, CDC73, CDKN1B, CDKN1C, CEBPA, CREBBP, DDB2, DDX41, DICER1, DIS3L2, DKC1, EP300, EPCAM, ERCC2, ETV6, EXT1, EXT2, EZH2, FANCA, FH, GATA2, GPC3, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, MAX, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NHP2, NKX2-1, NRAS, NSD1, PHOX2B, PMS2, POLH, PRF1, PRKAR1A, PTCH1, PTEN, PTPN11, RAD51C, RAF1, RB1, RECQL4, RET, RIT1, RPL5, RPS7, RUNX1, SAMD9L, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SHOC2, SMAD4, SMARCA4, SMARCB1, SMARCE1, SOS1, SOS2, STK11, SUFU, TERC, TERT, TINF2, TMEM127, TP53, TRIM37, TSC1, TSC2, VHL, WRAP53, WRN, WT1, XPA, XPC</i>

\* For our BRCA1, BRCA2 panels, please visit our designated NGS panel webpage: <https://www.centogene.com/diagnostics/ngs-panels/oncology>

# Going The Extra Mile

All our high quality NGS panels detect single nucleotide variants (SNV), small insertions / deletions (InDels), and NGS-based deletion / duplication (CNV) analysis in one single assay – ultimately providing the most complete NGS panels for the maximum diagnostic yield.

---

## **Deletion / Duplication**

High resolution NGS-based CNV analysis to detect larger deletions and duplications is included in all our panels at no extra cost. Deletion / duplications constitute 5 – 10% of disease-causing variants. By including CNV analysis in our panels, the potential of providing the most accurate diagnosis increases.

---

## **Improved Interpretation**

CENTOGENE's Biodatabank, the world's largest real-world data repository for rare and neurodegenerative diseases enables access to more than 31 million unique variants for best medical interpretation.

---

## **Variant Reclassification Program**

All our panels are automatically entered into our variant reclassification program. This program supports the identification of new genetic evidence, and physicians will be notified free of charge for life.

FOR ORDERING

**[www.centoportal.com](http://www.centoportal.com)**

FOR MORE INFORMATION

**[www.centogene.com](http://www.centogene.com)**

CENTOGENE GmbH

Am Strande 7

18055 Rostock

Germany

CENTOGENE GmbH is a subsidiary of CENTOGENE N.V.

PARTNER SUPPORT

**[customer.support@centogene.com](mailto:customer.support@centogene.com)**

+49 381 80 113-416

FOR US PARTNERS

**[customer.support-us@centogene.com](mailto:customer.support-us@centogene.com)**

+1 617 580-2102

Rostock - CLIA #99D2049715

